Click on headlines below to download research
All the bases loaded for ASIT011
ASIT biotech | 03/04/2019
ASIT’s FY18 preliminary results were dominated by the initiation of the second Phase III study of gp-ASIT+ where randomisation is now complete. The…
Supportive data on ASIT’s short-course therapy
ASIT biotech | 14/03/2019
ASIT has announced the publication of mode of action data from its first Phase III study for its gp-ASIT+ product for grass pollen allergies. This is supportive…
Supportive data on ASIT’s short-course therapy
ASIT biotech | 06/03/2019
ASIT has announced the publication of mode of action data from its first Phase III study for its gp-ASIT+ product for grass pollen allergies. This is supportive…
Ahead of schedule on gp-ASIT+
ASIT biotech | 26/02/2019
In a transparent announcement, ASIT Biotech’s board has released the conclusions from its recent meeting. Recruitment for the pivotal Phase III study…
New year, renewed focus
ASIT biotech | 17/01/2019
ASIT has announced renewed focus on its most advanced product, gp-ASIT+ for grass pollen allergies, which coincides with some changes in senior management.…
The 82-centre gp-ASIT+ Phase III study launches
ASIT biotech | 20/11/2018
In a well-received announcement, ASIT has launched the confirmatory Phase III study on gp-ASIT+ for grass pollen allergy with study centres in six European…
Setting the stage for the confirmatory Phase III
ASIT biotech | 27/09/2018
ASIT Biotech’s H1 results statement included an outline of its preparations for the confirmatory Phase III study of its short-course gp-ASIT+ for…
All go on Phase III
ASIT biotech | 16/07/2018
On July 11 ASIT biotech raised €12m in commitments in a heavily oversubscribed convertible bond placement. In raising this additional capital, ASIT…
Executive interview – ASIT Biotech
Executive interview – ASIT Biotech | 16/07/2018
ASIT Biotech is a Belgian biotechnology company focused on late-stage clinical development of allergy immunotherapies (AITs). Its first product in Phase…